Clinical Research Directory
Browse clinical research sites, groups, and studies.
Combined Kidney and Hematopoietic Stem Cell Transplantation for Tolerance Induction
Sponsor: Rabin Medical Center
Summary
Combined transplantation of kidney and bone marrow between HLA-matched sibling donor-recipient pairs to induce immune tolerance in order to enable complete discontinuation of immunosuppressive therapy without kidney rejection. Hematopoietic stem cells are collected from the donor 4 to 8 weeks before kidney transplantation, CD34 cells are enriched by positive selection and cryopreserved. The day after kidney transplantation the recipient starts conditioning therapy with thymoglobuline, total lymphoid irradiation, steroids, tacrolimus and mycophenolate mofetil. Eleven days after kidney transplantation the stem cell graft is thawed and infused to the recipient. If mixed donor chimerism is successfully maintained more than 6 months without rejection, then immunosuppression may be tapered off until complete discontinuation.
Official title: Combined Kidney and Hematopoietic Stem Cell Transplantation for Tolerance Induction Between Matched Sibling Donor-recipient Pairs
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2016-01-19
Completion Date
2026-12-31
Last Updated
2021-10-28
Healthy Volunteers
No
Conditions
Interventions
Combined kidney and bone marrow transplantation
Combined kidney and bone marrow transplantation
Locations (1)
Rabin Medical Center
Petah Tikva, Israel